Citius Pharmaceuticals effects 1-for-25 reverse stock split to regain Nasdaq bid price compliance

Citius Pharmaceuticals, Inc.

Reverse split at 1-for-25 ratio effective Nov 25, 2024; split-adjusted trading begins Nov 26.
Authorized shares reduced from 400M to 16M; issued shares from ~193M to ~7.7M.
No fractional shares issued; fractional interests rounded up to nearest whole share.
Intended to regain compliance with Nasdaq minimum $1.00 bid price requirement.
Trading symbol remains CTXR; new CUSIP 17322U306.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.